Quantification of glucosylceramide in plasma of Gaucher disease patients (original) (raw)
LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population
Laura López de Frutos
Clinical Chemical Laboratory Medicine, 2020
View PDFchevron_right
Enzymic diagnosis in 27 cases with Gaucher's disease
Klaus Harzer
Clinica Chimica Acta, 1980
View PDFchevron_right
12 A practical approach to diagnosis and management of Gaucher's disease
Mark Sonderup
Baillière's Clinical Haematology, 1997
View PDFchevron_right
Twenty- five years of biochemical diagnosis of Gaucher disease: the Egyptian experience
Dr. Zeinab Abdallah
Heliyon, 2019
View PDFchevron_right
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response
Maria Lucia G Ferraz
Blood, 2011
View PDFchevron_right
Place of cytology in the diagnosis of Gaucher disease: About a case
Ibtissam Mhirig
GSC Advanced Research and Reviews, 2022
View PDFchevron_right
Laboratory diagnosis and follow-up of Romanian Gaucher disease patients
Alexandra Craciun
Romanian Journal of Laboratory Medicine, 2017
View PDFchevron_right
Validity of β-d-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients
Maria Calevo
Clinical Biochemistry, 2014
View PDFchevron_right
Plasmalogen levels in Gaucher disease
Theodoros Marinakis
Blood Cells, Molecules, and Diseases, 2008
View PDFchevron_right
Conditions affecting the activity of glucocerebrosidase purified fom spleens of control subjects and patients with type 1 Gaucher disease
Sonja Van Weely
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1990
View PDFchevron_right
Gaucher disease: A diagnostic challenge for internists
Erika Poggiali
European Journal of Internal Medicine, 2014
View PDFchevron_right
Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
Ulrike Grittner
PLoS ONE, 2013
View PDFchevron_right
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
T Billette
International journal of molecular sciences, 2017
View PDFchevron_right
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
Ana Martins
Journal of Inherited Metabolic Disease, 2008
View PDFchevron_right
Application of a comprehensive protocol for the identification of Gaucher disease in Brazil
Alexandre Mello
American Journal of Medical Genetics Part A, 2005
View PDFchevron_right
Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
Paskal Cullufi
International Journal of Molecular Sciences
View PDFchevron_right
Correlation among Genotype, Phenotype, and Biochemical Markers in Gaucher Disease: Implications for the Prediction of Disease Severity
Michael Fietz
Molecular Genetics and Metabolism, 2002
View PDFchevron_right
Clinical manifestations and management of Gaucher disease
Silvia Linari
Clinical Cases in Mineral and Bone Metabolism, 2015
View PDFchevron_right
The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease
Olle Nilsson
Biochimica et biophysica acta, 1982
View PDFchevron_right
Clinical and diagnostic findings of 19 Gaucher patients in Albania
Virtut Velmishi
View PDFchevron_right
Oligosaccharide excretion in adult Gaucher disease
Ron Wevers
Journal of Inherited Metabolic Disease, 1998
View PDFchevron_right
Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease
Bruno Bembi
2002
View PDFchevron_right
Haematological manifestations and complications of Gaucher disease
Gregory Pastores
Current Opinion in Hematology, 2013
View PDFchevron_right
Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: Significant differences between Type I and Type III
Olle Nilsson
Clinical Genetics, 2008
View PDFchevron_right
Gaucher’s Disease in a 2 Years Old Child: A Case Report
Dr. dr. I Gusti Ayu Putu Eka Pratiwi, MKes, SpAK
American Journal of Pediatrics, 2020
View PDFchevron_right
Laboratory and genetic evaluation of Gaucher disease Labordiagnostik bei Morbus Gaucher
Goar MB
View PDFchevron_right
Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes – A statistical insight
Agnieszka Ługowska
Molecular Genetics and Metabolism, 2018
View PDFchevron_right
Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1-gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease
Roberto Giugliani
Clinical Biochemistry, 2007
View PDFchevron_right